Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study - Top-Institutions - MDSpire

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • By

  • Andrew Blauvelt

  • H. Chih-Ho Hong

  • Norito Katoh

  • Richard G. Langley

  • Vivian Laquer

  • Aleksandra Lesiak

  • Ketty Peris

  • Julien Seneschal

  • Juan-Francisco Silvestre

  • Richard B. Warren

  • Andreas Wollenberg

  • Matthew Zirwas

  • Niels Højsager Bennike

  • Farzaneh Safavimanesh

  • Ann-Marie Tindberg

  • Kristian Reich

  • February 5, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunodermatology
    • Clinical Research

  • #3

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunology

  • #5

    University of California, San Francisco (UCSF) School of Medicine
    University of California, San Francisco (UCSF) School of Medicine

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunodermatology
    • Clinical Research

Original Source(s)

Extended Safety and Effectiveness of Tralokinumab in Individuals with Moderate-to-Severe Atopic Dermatitis Over a 6-Year Period: Final Outcomes from the ECZTEND Open-Label Extension Study

  • by Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich

  • February 5, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

Case Report: Intravenous transplantation of autologous adipose tissue-derived mesenchymal stem cells attenuated atopic dermatitis